Never started a new thread before but would like to get your views on the following:
1) Dir appointed 16 Nov 2021 - ex partner of Deloittes with M&A experience PLUS a Dr Elliott exec dir within the global network strategy team at CSL Behring where she is responsible for business value delivery from a billion dollar global capital expansion portfolio.
2) Fin Review y/day p 40 "CSL (in) $19b deal" CSL has acquired, & has a strategy to "turbocharge the growth of Swiss pharma co Vifor.."
3) FR same place: "Injectible iron is highly underutilised.....physicians will tell you about patients where it has just basically changed their lives" (per CSL CEO). Per article, 'Vifors key injectible iron product -Ferinject - is used mainly in the treatment of chronic kidney disease and in patient blood management'.
Just maybe, there's a thread there with potentially significant ramifications for PIQ ?? Regards to all.
PIQ Price at posting:
98.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)